-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our target price to $92 from $86 based on our discounted cash flow analysis. We widen our 2026 loss per share forecast to -$2.62 from -$2.42 and our 2027 loss per share estimate to -$0.66 from -$0.35. IONS demonstrated significant positive momentum, reporting a very strong Q1 and significantly beating revenue and LPS estimates. Total Q1 revenue surged to $246M (+87% Y/Y) driven by robust operational execution and accelerating demand for Ionis' key commercial products. TRYNGOLZA (Olezarsen) sales rose by a record 350% Y/Y and DAWNZERA sales increased by 125% Q/Q in Q1. The upcoming launch of Olezarsen in severe hypertriglyceridemia (sHTG) indication targets a large addressable market of over 3 million patients and positions the treatment to be Ionis' first wholly-owned blockbuster medicine, in our view. We think the pipeline progress and successful operational execution position Ionis well for substantial near-term growth, reinforcing its evolution into a fully integrated commercial biotech company.